Opko Health Stock Price, News & Analysis

OPKO Health (NASDAQ:OPK) has scheduled its Second Quarter 2025 financial results announcement for July 31, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss operating and financial results for the three and six months ended June 30, 2025.

Participants can pre-register for the call through a provided link, or join by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A replay will be available until August 7, 2025, accessible via phone or webcast.

OPKO Health (NASDAQ: OPK) and Entera Bio announced their abstract on oral GLP-2 tablet for Short Bowel Syndrome (SBS) treatment has been selected for presentation at the 47th ESPEN Congress in Prague this September.

The research combines OPKO's proprietary long-acting GLP-2 agonist with Entera's N-Tab™ technology, aiming to provide an oral alternative to GATTEX® (teduglutide), which currently requires daily subcutaneous injections. The oral tablet format could potentially improve treatment compliance and enable more personalized care for SBS patients.

NextPlat (NASDAQ: NXPL) has issued an interim CEO update following the unexpected passing of former CEO Charles M. Fernandez. Interim CEO David Phipps outlined the company's strategic direction, focusing on two main divisions: Healthcare and E-Commerce.

In the Healthcare division, which represents the largest part of their business, NextPlat plans to expand contracted 340B and long-term care services, implement operational efficiencies, and pursue specialty medication accreditation. Key initiatives include exploring nationwide licensing for e-Commerce mail-order sales, adding compounding services, and targeting non-insured cash sales.

For the E-Commerce division, despite facing challenges from U.S.-China tariffs affecting product launches like their Florida Sunshine vitamin brand, the company aims to scale globally through strategic acquisitions, new marketplace launches, and partnerships. Notable developments include expanding their partnership with OPKO Health (NASDAQ: OPK) for health product sales in China and exploring UK/EU markets for their vitamin brand.

The company has also committed to implementing a previously announced stock buyback program and improving shareholder transparency while focusing on generating positive operating results.

OPKO Health (NASDAQ:OPK) announced its participation in the upcoming 3rd Annual Piper Sandler Virtual Obesity Symposium on June 26, 2025. The company's management will engage in a fireside discussion moderated by Edward Tentoff, Managing Director and Senior Biotechnology Analyst at Piper Sandler. Interested investors can register for the virtual event through their Piper Sandler representatives.

OPKO Health (NASDAQ: OPK) and Entera Bio announced their abstract for oral OPK-88006, a novel dual GLP-1/glucagon peptide treatment, has been selected for presentation at ENDO 2025 in San Francisco. The treatment is being developed as both a once-daily tablet and a weekly subcutaneous injection for patients with obesity and metabolic disorders.

The oral program combines OPKO's long-acting oxyntomodulin analog with Entera's N-Tab™ technology. The companies plan to file an IND application with the FDA later in 2025, followed by Phase 1 clinical studies. The presentation will showcase new pharmacologic and pharmacokinetic in vivo data at the conference on July 13, 2025.

OPKO Health's subsidiary ModeX Therapeutics has formed a Scientific Advisory Board comprising four distinguished leaders in immunology and oncology: Drs. John Heymach, Ronald Levy, Myron Cohen, and Rafi Ahmed. The board will provide expertise for ModeX's development of next-generation multispecific antibodies and vaccines using its MSTAR platform technology. The company currently has two assets in clinical trials and multiple pre-IND assets. The advisory board members bring extensive experience in immunology, cancer treatment, HIV research, and vaccine development. ModeX's platform focuses on creating multispecific medicines that can target multiple disease pathways simultaneously, aiming to address complex conditions that are currently untreatable with single-target approaches.

OPKO Health (NASDAQ: OPK) has announced its participation in two upcoming investor conferences. The company will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq on May 20 in New York City, featuring one-on-one investor meetings and a fireside discussion at 9:00 a.m. ET. Additionally, OPKO will participate in the Jefferies Global Healthcare Conference from June 3-5 at the Marriott Marquis in New York City, with investor meetings and a fireside chat scheduled for June 4th at 11:05 a.m. ET. Both fireside discussions will be webcast live and available for replay on OPKO Health's website.

OPKO Health reports Q1 2025 financial results with key developments in its business portfolio. The company signed a definitive agreement to sell BioReference's oncology testing assets to Labcorp for up to $225 million. OPKO partnered with Entera Bio to develop an oral GLP-1/glucagon tablet for obesity treatment, with OPKO holding a 60% stake.

Financial highlights include consolidated revenues of $149.9 million, down from $173.7 million in Q1 2024. The company posted a net loss of $67.6 million ($0.10 per share), improving from $81.8 million ($0.12 per share) year-over-year.

Notable progress includes Merck's Phase 1 trial of an Epstein-Barr virus vaccine and ModeX's advancement of four clinical candidates. The Board authorized an additional $100 million for stock repurchase, bringing total capacity to $200 million. Cash position stands strong at $449.7 million as of March 31, 2025.

OPKO Health (NASDAQ: OPK) has announced it will release its Q1 2025 financial and operating results on April 30, 2025 after U.S. market close. The company's senior management will host a conference call and live audio webcast at 4:30 p.m. Eastern time to discuss the results and provide financial guidance.

Participants can pre-register for the conference call through a provided link to receive a unique PIN for immediate access. Those unable to pre-register can dial 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast replay will be available approximately one hour after the call until May 7, 2025.